Thomas Pfaadt appointed as new Chief Financial Officer of Vita 34 AG
|
EQS-News: Vita 34 AG
/ Key word(s): Personnel
Thomas Pfaadt appointed as new Chief Financial Officer of Vita 34 AG
Leipzig, 1 August 2024 – The Supervisory Board of Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), the leading cell bank in Europe and the third largest in the world, has appointed Mr. Thomas Pfaadt (51) as new Chief Financial Officer effective today. Thomas Pfaadt has more than 20 years of professional experience in various areas of finance. After studying business administration at Goethe University Frankfurt am Main, he held positions of responsibility in the areas of M&A and Corporate Finance at PricewaterhouseCoopers and DZ Bank. He then took on management roles in these areas at two leading German companies in the healthcare industry, before taking on the position of CFO and Managing Director at C-Lecta GmbH, a global biotechnology company for enzyme products, in 2018. "We are delighted to have won Thomas Pfaadt, a CFO with a wealth of experience, for our company," says Jakub Baran, CEO of Vita 34 AG. "With his appointment, the Management Board is now complete again with three members after a few months of vacancy." As a member of the Management Board of Vita 34 AG, Thomas Pfaadt will be mainly responsible for the areas of Finance, Controlling, Accounting, Procurement and Administration. His appointment is initially for a term of three years. Contact: Company Profile Vita 34 was founded in Leipzig in 1997 and today is by far the leading cell bank in Europe and the third largest worldwide. As the first private umbilical cord blood bank in Europe and a pioneer in cell banking, the company has since offered the collection logistics, processing and storage of stem cells from umbilical cord blood, umbilical cord tissue and other postnatal tissues as a full-service provider for cryopreservation. Due to the expansion of the business model following the merger with PBKM, the company intends to invest in the areas of Cell & Gene therapies and CDMO. The body's own cells are a valuable starting material for medical cell therapy and are kept alive in the vapor of liquid nitrogen. Customers from about 50 countries have already provided for the health of their families with around one million units of stored biological material at Vita 34.
01.08.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Vita 34 AG |
| Deutscher Platz 5a | |
| 04103 Leipzig | |
| Germany | |
| Phone: | +49(0341)48792-40 |
| Fax: | +49(0341)48792-39 |
| E-mail: | ir@vita34.de |
| Internet: | www.vita34.de |
| ISIN: | DE000A0BL849 |
| WKN: | A0BL84 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1959319 |
| End of News | EQS News Service |
|
|
1959319 01.08.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.